Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2012. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) under the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding internal plan transactions rather than a financial performance report.
Material Changes
The filing details an increase in the notional allocation of Ordinary share ADRs for specific directors and connected persons on February 17, 2012. This adjustment resulted from a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan at a price of $44.88 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly addresses compliance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Important Facts for Investors
- Transaction Date: The notional allocation increase occurred on February 17, 2012.
- Transaction Price: The ADR price used for the re-valuation was $44.88.
- Participants: The transaction involved Dr. M M Slaoui (18 ADRs), Dr. K Slaoui (4 ADRs), Mr. W C Louv (8 ADRs), and Dr. D Pulman (12 ADRs).
- Plan Type: The activity relates to the US Retirement Savings Plan, which is notionally held in GSK Ordinary share ADRs.